VTRS - Viatris Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Canonsburg,
United States
Type: Equity
VTRS price evolution
VTRS
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $991.9 | $1309.6 | $629.2 | $506.6 |
| Short term investments | ||||
| Net receivables | $3700.4 | $3738.5 | $3607.3 | $3497.5 |
| Inventory | $3469.7 | $3671.9 | $3641.5 | $3664.3 |
| Total current assets | $12976.1 | $10932 | $9778 | $9630.3 |
| Long term investments | ||||
| Property, plant & equipment | $2759.6 | $2926.6 | $2983.2 | $3007.8 |
| Goodwill & intangible assets | $29048.2 | $31558.6 | $32616.9 | $33274.8 |
| Total noncurrent assets | $34709.4 | $37810.6 | $38917.2 | $39659.9 |
| Total investments | ||||
| Total assets | $47685.5 | $48742.6 | $48695.2 | $49290.2 |
| Current liabilities | ||||
| Accounts payable | $1938.2 | $1989.1 | $1962 | $1957.5 |
| Deferred revenue | ||||
| Short long term debt | $1943.4 | $1307.5 | $1357.6 | $713.3 |
| Total current liabilities | $7777.4 | $6834 | $6523.8 | $6108.1 |
| Long term debt | $16188.1 | $17076.9 | $17246 | $18069.4 |
| Total noncurrent liabilities | $19440.7 | $21043 | $21328.1 | $22254.2 |
| Total debt | $18131.5 | $18384.4 | $18603.6 | $18782.7 |
| Total liabilities | $27218.1 | $27877 | $27851.9 | $28362.3 |
| Shareholders' equity | ||||
| Retained earnings | $4639.7 | $5553 | $5369.1 | $5252.5 |
| Other shareholder equity | -$2747.4 | -$3208.5 | -$3005.6 | -$2764.6 |
| Total shareholder equity | $20467.4 | $20865.6 | $20843.3 | $20927.9 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $991.9 | $1259.9 | $701.2 | $844.4 |
| Short term investments | $84.9 | |||
| Net receivables | $3700.4 | $3814.5 | $4266.4 | $4843.8 |
| Inventory | $3469.7 | $3519.5 | $3977.7 | $5471.9 |
| Total current assets | $12976.1 | $10635.4 | $10902.9 | $12867.5 |
| Long term investments | $47.9 | |||
| Property, plant & equipment | $2759.6 | $3283.8 | $3188.6 | $3459.9 |
| Goodwill & intangible assets | $29048.2 | $33032.9 | $38247.9 | $42030.2 |
| Total noncurrent assets | $34709.4 | $39386.8 | $43939.9 | $48685.5 |
| Total investments | ||||
| Total assets | $47685.5 | $50022.2 | $54842.8 | $61553 |
| Current liabilities | ||||
| Accounts payable | $1938.2 | $1158 | $1657.4 | $1904.2 |
| Deferred revenue | ||||
| Short long term debt | $1943.4 | $1259.1 | $3370.5 | $3409.4 |
| Total current liabilities | $7777.4 | $6746.2 | $9884.4 | $10562.9 |
| Long term debt | $16188.1 | $18015.2 | $19717.1 | $22429.2 |
| Total noncurrent liabilities | $19440.7 | $22203.7 | $24465.7 | $28036 |
| Total debt | $18131.5 | $19274.3 | $23087.6 | $25838.6 |
| Total liabilities | $27218.1 | $28949.9 | $34350.1 | $38598.9 |
| Shareholders' equity | ||||
| Retained earnings | $4639.7 | $5175.6 | $3688.8 | $5361.2 |
| Other shareholder equity | -$2747.4 | -$2758.9 | -$1744.3 | -$858 |
| Total shareholder equity | $20467.4 | $21072.3 | $20492.7 | $22954.1 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3837.3 | $3941.9 | $3918.6 | $3729.1 |
| Cost of revenue | $2240.8 | $2250.6 | $2310 | $2186.9 |
| Gross Profit | $1596.5 | $1691.3 | $1608.6 | $1542.2 |
| Operating activities | ||||
| Research & development | $202.8 | $211.2 | $208.3 | $182.9 |
| Selling, general & administrative | $1605.8 | $1053.5 | $1031.9 | $958.9 |
| Total operating expenses | $2051 | $1239.6 | $1239.4 | $1142.4 |
| Operating income | -$454.5 | $451.7 | $369.2 | $399.8 |
| Income from continuing operations | ||||
| EBIT | -$714.1 | $543.7 | $476.7 | $469.7 |
| Income tax expense | -$89.4 | $70.6 | $69 | $98 |
| Interest expense | $140.9 | $141.5 | $143.7 | $147 |
| Net income | ||||
| Net income | -$765.6 | $331.6 | $264 | $224.7 |
| Income (for common shares) | -$765.6 | $331.6 | $264 | $224.7 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15426.9 | $16262.7 | $17886.3 | $11946 |
| Cost of revenue | $8988.3 | $9765.7 | $12310.8 | $8149.3 |
| Gross Profit | $6438.6 | $6497 | $5575.5 | $3796.7 |
| Operating activities | ||||
| Research & development | $805.2 | $662.2 | $751.1 | $555.1 |
| Selling, general & administrative | $4650.1 | $4179.1 | $4529.2 | $3344.6 |
| Total operating expenses | $5672.4 | $4882.1 | $5609.5 | $4007.5 |
| Operating income | $766.2 | $1614.9 | -$34 | -$210.8 |
| Income from continuing operations | ||||
| EBIT | $776 | $3405.6 | -$28.2 | -$223.4 |
| Income tax expense | $148.2 | $734.6 | $604.7 | -$51.3 |
| Interest expense | $573.1 | $592.4 | $636.2 | $497.8 |
| Net income | ||||
| Net income | $54.7 | $2078.6 | -$1269.1 | -$669.9 |
| Income (for common shares) | $54.7 | $2078.6 | -$1269.1 | -$669.9 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$765.6 | $331.6 | $264 | $224.7 |
| Operating activities | ||||
| Depreciation | $644.4 | $679.4 | $686.7 | $730 |
| Business acquisitions & disposals | $316.1 | $48 | -$667.7 | |
| Stock-based compensation | $55.8 | $43.1 | $39.2 | $42.6 |
| Total cash flows from operations | $479.4 | $834.1 | $514.9 | $971.2 |
| Investing activities | ||||
| Capital expenditures | -$164.9 | -$95.6 | -$54.7 | -$47.8 |
| Investments | ||||
| Total cash flows from investing | $115.8 | -$53.8 | -$76.6 | -$749.5 |
| Financing activities | ||||
| Dividends paid | -$144 | -$143.9 | -$143.9 | -$143.8 |
| Sale and purchase of stock | $0.6 | $0.8 | $0.8 | -$249.1 |
| Net borrowings | -$499.7 | -$22.9 | -$181.5 | -$545.5 |
| Total cash flows from financing | -$926.1 | -$97.6 | -$303.5 | -$974.7 |
| Effect of exchange rate | $12.7 | -$2.3 | -$14.1 | $1.2 |
| Change in cash and equivalents | -$318.2 | $680.4 | $120.7 | -$751.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $54.7 | $2078.6 | -$1269.1 | -$669.9 |
| Operating activities | ||||
| Depreciation | $2740.5 | $3027.6 | $4506.5 | $2216.1 |
| Business acquisitions & disposals | -$303.6 | $1950 | $373.7 | $435.8 |
| Stock-based compensation | $180.7 | $116.4 | $111.2 | $79.2 |
| Total cash flows from operations | $2799.6 | $2952.6 | $3016.9 | $1231.8 |
| Investing activities | ||||
| Capital expenditures | -$363 | -$392.2 | -$438.9 | -$240.9 |
| Investments | -$0.3 | -$0.4 | -$57.8 | |
| Total cash flows from investing | -$764.1 | $1520.5 | -$117.8 | -$301.1 |
| Financing activities | ||||
| Dividends paid | -$575.6 | -$581.6 | -$399 | |
| Sale and purchase of stock | -$246.9 | $3.3 | $0.6 | |
| Net borrowings | -$1249.6 | -$3280.1 | -$2099.1 | -$401.3 |
| Total cash flows from financing | -$2301.9 | -$3877.9 | -$3012 | -$605.7 |
| Effect of exchange rate | -$2.5 | -$38.9 | -$30.9 | $33.8 |
| Change in cash and equivalents | -$268.9 | $556.3 | -$143.8 | $358.8 |
News
|
Viatris Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance
8 Mar 2024
|
|
Insider Sell: President of Greater China Xiangyang Ni Sells 21,532 Shares of Viatris Inc (VTRS)
GuruFocus.com via Yahoo Finance
5 Mar 2024
|
|
Viatris Inc. (NASDAQ:VTRS) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
5 Mar 2024
|
|
13 Best Pharma Dividend Stocks To Buy in 2024
Insider Monkey via Yahoo Finance
5 Mar 2024
|
|
Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
Zacks via Yahoo Finance
5 Mar 2024
|
|
Revance announces $100 million stock offering By Investing.com
Investing.com
4 Mar 2024
|
|
Revance sets $100 million stock offering at $6.25 per share
Investing.com
4 Mar 2024
|
|
Revance sets $100 million stock offering at $6.25 per share
Investing.com
3 Mar 2024
|
|
Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates
Zacks via Yahoo Finance
28 Feb 2024
|
|
Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving...
Benzinga
28 Feb 2024
|
Fundamentals
| Market cap | $13.64B |
|---|---|
| Enterprise value | $30.78B |
| Shares outstanding | 1.20B |
| Revenue | $15.43B |
|---|---|
| EBITDA | $3.52B |
| EBIT | $776.00M |
| Net Income | $54.70M |
| Revenue Q/Q | -1.00% |
| Revenue Y/Y | -5.14% |
| P/E ratio | 249.37 |
|---|---|
| EV/Sales | 2.00 |
| EV/EBITDA | 8.75 |
| EV/EBIT | 39.67 |
| P/S ratio | 0.88 |
| P/B ratio | 0.59 |
| Book/Share | 19.33 |
| Cash/Share | 0.83 |
| EPS | $0.05 |
|---|---|
| ROA | 0.11% |
| ROE | 0.26% |
| Debt/Equity | 1.33 |
|---|---|
| Net debt/EBITDA | 7.46 |
| Current ratio | 1.67 |
| Quick ratio | 1.22 |